Browse the evidence

Substituting LNCSBs for SSBs was associated with a reduction in body mass index (BMI) by 0.32 (95% CI, -0.58 to -0.07).

Practitioners may use BMI changes as an additional metric for assessing the effectiveness of LNCSBs in dietary interventions.

Postintervention weight change averaged -3.7 ± 9.5%, with greater weight loss in the DSE than the ILI group.

Practitioners should note that weight loss outcomes vary significantly between intervention types.

Diet is a prominent modifiable element driving weight gain and adiposity.

Practitioners should focus on dietary modifications to address obesity.

The intervention group achieved a mean body weight change of −9.5% (±4.1) with 90% of participants losing ≥ 5%.

Practitioners can consider remote interventions as effective for weight loss in older adults.

Remote interventions are feasible for older adults and can support fidelity, adherence, engagement, and clinically significant weight loss.

Practitioners can confidently use remote interventions to promote healthy aging in older adults.

Higher protein intake (HP) and moderate protein intake (MP) groups showed greater increases in skeletal muscle mass (SMM) compared to the lower protein intake (LP) group, with increases of 5.1% and 5.4% respectively, versus 2.3% for LP (P < 0.05).

Practitioners should encourage higher protein intake in older women to enhance muscle gains during resistance training.

Protein intake is a moderating variable for body recomposition in older women undergoing resistance training, with low protein intake having a less favorable effect.

Emphasizing adequate protein intake is crucial for optimizing body recomposition in older women engaged in resistance training.

Orforglipron has advanced through Phase 3 clinical development, demonstrating significant reductions in hemoglobin A1c and body weight (up to 7.9%) with favorable tolerability.

Practitioners can consider Orforglipron as an effective option for managing hemoglobin A1c and body weight.

Weight loss reduces the recurrence of symptomatic atrial fibrillation.

Weight management should be a focus in the treatment plan for patients with AF.

Oral semaglutide, 50 mg, led to a mean percentage change in body weight of -14.3% compared to -1.3% with placebo.

Oral semaglutide is effective for significant weight loss in this population.

84.3% of participants on semaglutide achieved a 5% or greater body weight reduction compared to 17.2% on placebo.

A high proportion of patients on semaglutide can expect significant weight loss.

R-ESG offered higher total body weight loss (TBWL%) than GLP1/GIP-RA at 3 months (11.2% vs. 4.3%, p < .001), 6 months (13.5% vs. 6.8%, p < .001), and 12 months (13.4% vs. 9.2%, p = .07).

Practitioners may consider R-ESG as a more effective option for weight loss in patients experiencing weight recidivism after sleeve gastrectomy.

GLP1/GIP-RA achieved significantly lower TBWL% in patients with prior SG compared to those with intact stomach at 3 months (4.3% vs. 5.7%, p = .02), 6 months (6.8% vs. 9.2%, p = .02), and 12 months (9.2% vs. 12.7%, p = .03).

Practitioners should be aware that GLP1/GIP-RA may be less effective for weight loss in patients with prior sleeve gastrectomy compared to those with intact stomachs.

Excess adiposity is associated with worse outcomes in breast cancer survivors.

Practitioners should consider addressing excess adiposity in breast cancer survivors to improve health outcomes.

Excess adiposity can be targeted to improve breast cancer outcomes.

Interventions aimed at reducing excess adiposity may enhance survivorship and quality of life for breast cancer survivors.

Novel incretin-based therapies have gained popularity due to their effectiveness in achieving substantial weight loss.

Healthcare providers should consider incretin-based therapies as effective options for weight management.

Tirzepatide-associated improvements in cardiometabolic risk factors are positively related to the degree of weight reduction.

Weight reduction through tirzepatide can lead to significant improvements in cardiometabolic health.

Improvements in triglycerides, HDL cholesterol, LDL cholesterol, and non-HDL cholesterol were primarily observed after weight reductions greater than 10%.

Targeting a weight reduction of over 10% may be necessary for significant improvements in lipid profiles.

The steepest improvements in cardiometabolic risk factors occurred between less than 5% and less than 20% weight reduction.

Practitioners should note that even modest weight loss can lead to significant health improvements, particularly within the 5-20% range.

GLP-1 receptor agonists (GLP-1RAs) and dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonists (GLP-1/GIPRA) significantly reduce body weight and adiposity.

Practitioners can expect significant weight loss and reduction in adiposity with GLP-1RA and GLP-1/GIPRA therapies.

Correcting hormonal deficiencies may improve exercise capacity and reduce major cardiac events.

Clinicians should consider hormonal assessments in patients at risk of cardiovascular events.

Patients in the clinical pharmacist cohort achieved a mean body weight reduction of 9.32% compared to 5.11% body weight reduction for patients in the primary care physician cohort.

Incorporating clinical pharmacists in weight management can lead to greater weight loss outcomes.

Pharmacists can effectively evaluate and monitor the use of GLP-1 therapy in weight management patients.

Utilizing pharmacists in weight management can enhance patient care and therapy outcomes.

Patients receiving email-based health coaching and Semaglutide therapy lost a mean weight of 9.52% over 5 months.

Email-based coaching combined with Semaglutide can be effective for weight loss in overweight and obese patients.